Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380235 | 1.00 | KEAP1 (0.50) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL16965686 | 1.00 | KEAP1 (0.50) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL18766237 | 1.00 | KEAP1 (0.50) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL24015864 | 0.86 | MTNR1A (0.49) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL24015849 | 0.86 | MTNR1A (0.49) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL30819117 | 0.86 | MTNR1A (0.49) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL11214430 | 0.86 | HDAC1 (0.62) | KEAP1NFE2L2HDAC1LMNAALDH1A1 | |
| SCHEMBL28707494 | 0.85 | LMNA (0.52) | KEAP1NFE2L2HDAC1LMNAALDH1A1 | |
| SCHEMBL16847210 | 0.85 | LMNA (0.53) | KEAP1NFE2L2GPR88HDAC1PHGDH | |
| SCHEMBL17076029 | 0.85 | LMNA (0.53) | KEAP1NFE2L2GPR88HDAC1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| EP-2507210-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | Novartis AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| WO-2011067306-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | KEAP1 187/4885NFE2L2 1324/4885GPR88 2506/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | KEAP1 812/4885NFE2L2 1663/4885GPR88 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.